Publication
Clinical and biological significance of RAS mutations in multiple myeloma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerMultiple Myelomacivic_curation1.00
- geneKRAScivic_curation1.00
- geneNRAScivic_curation1.00
- variantKRAS G12civic_curation1.00
- variantKRAS G13civic_curation1.00
- variantKRAS Q61civic_curation1.00
- variantNRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 18528420
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G122 | ||||||||
| (prognostic) | Multiple Myeloma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID377The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival. PMID 18528420 · Chng et al., 2008 · Open in CIViC | civic |
| 〃 | Multiple Myeloma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID487In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC | civic |
| KRAS G131 | ||||||||
| (prognostic) | Multiple Myeloma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID488In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC | civic |
| KRAS Q611 | ||||||||
| (prognostic) | Multiple Myeloma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID489In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC | civic |
| NRAS Mutation1 | ||||||||
| (prognostic) | Multiple Myeloma | Prognostic | B | Supports N/A | 4 | accepted | EID496In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival. PMID 18528420 · Chng et al., 2008 · Open in CIViC | civic |